APA

Lukas M., Malickova K., Kolar M., Bortlik M., Vasatko M., Machkova N., Hruba V., Duricova D. & Lukas M. (20210615). Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. : Journal of Crohn's & colitis.

Chicago

Lukas Martin, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N, Hruba V, Duricova D and Lukas Milan. 20210615. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. : Journal of Crohn's & colitis.

Harvard

Lukas M., Malickova K., Kolar M., Bortlik M., Vasatko M., Machkova N., Hruba V., Duricova D. and Lukas M. (20210615). Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. : Journal of Crohn's & colitis.

MLA

Lukas Martin, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N, Hruba V, Duricova D and Lukas Milan. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. : Journal of Crohn's & colitis. 20210615.